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1. Introduction
Thyroid hormones (TH) are critical for early brain development, somatic growth, and bone
and  pubertal  maturation.  Moreover,  they  are  crucial  for  survival,  both  in  rodents  and
humans. In many respects, (TH) may be viewed as tissue growth factors. Effects on growth
and development are classified as genomic actions mediated via stimulation of mRNA for
pituitary  growth  hormone  (GH)  synthesis,  secretion  and  sensitivity.  TH  potentiate  GH
stimulation of the synthesis and action of insulin-like growth factor 1 (IGF1) and stimula‐
tion of the production of different growth factors (epidermal growth factor, nerve growth
factor,  and erythropoietin).  Cartilage response to IGF1 and osteoblastic/osteoclastic  bone
remodeling  are  also  regulated  by  thyroid  hormones.  Unlike  insulin  and  cortisol  levels,
which  fluctuate  widely  in  response  to  food  ingestion  and  stress,  thyroid  hormones  are
typically maintained at a constant level that keeps the metabolic machinery functioning at
a proper rate (Zimmerman-Belsing et al., 2003).
In overt hypothyroidism, the severe impairment of linear growth leads to dwarfism, which is
characterised by limbs that are disproportionately short compared with the trunk.
Even in subclinical hypothyroidism, a condition of mild thyroid failure, growth velocity in
children is suboptimal.
In this chapter, the impact of TH on growth in different forms of hypothyroidism will be
discussed in light of thyroid hormone treatment in pediatric praxis.
© 2013 Saranac et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Causes of acquired primary hypothyroidism in childhood
Acquired primary hypothyroidism (AH) in children and adolescents is predominantly caused
by end-stage autoimmune disease arising from a chronic autoimmune thyroiditis (CAT). CAT
is the most common cause of AH in nonendemic goitre areas, and it afflicts up to 2% of children
and adolescents (Bartalena et al., 2007; Fisher, 1990; Raillison et al., 1975; Tomer & Huber,
2009; Fernandez-Soto et al., 1998). Unlike the overt goitrogenic form of CAT, the atrophic form
often remains hidden or misdiagnosed for years. Other causes of acquired hypothyroidism
include the following: late-onset thyroid dysgenesis and late-onset dyshormonogenesis;
decreased responsiveness to thyroid hormones; TSH deficiency; drug-induced, iatrogenic, or
endemic iodine deficiency; and chromosomal disorders and cystinosis (Fisher, 1990).
The importance of the thyroid gland for the human body is largely due to its production of
hormones necessary for appropriate energy levels and an active life. These products have
pleiotropic effects, which include exerting an immense array of hormonal activities (genomic
and non-genomic actions) and playing a critical role in early brain development, somatic
growth, bone maturation, and mRNA synthesis for more than 100 proteins that constantly
regulate the maintenance of all bodily functions. TH impact every tissue to such an extent that
a certain degree of thyroid dysfunction is highly likely to result in multiorgan failure thus often
mimicking various diseases (Weetman, 2003; Saranac et al., 2011).
3. Genomic and non–genomic actions of thyroid hormones
T3 binding by the nuclear thyroid receptors (TR) leads to responsive gene transcription, which
modulates synthesis of mRNA and proteins—which in turn mediate thyroid hormone effects
in various tissues. In the central nervous system, general genomic effects include stimulation
of cell migration and neuronal cell maturation and stimulation of dendritic arborisation,
synaptic density and increased myelogenesis. Gene products regulated by T3 in the CNS are
myelin basic protein, nerve growth factors and their receptors, neurotropin 3, neural cell
adhesion molecules, cerebellar PCP-2 and prostaglandin D2 synthase (Fisher & Grueters,
2008).
Genomic effects on growth and development include the following: stimulation of pituitary
growth hormone (GH) synthesis and secretion; potentiation of GH stimulation of insulin-like
growth factor (IGF) synthesis and action; stimulation of growth factor production (epidermal
growth factor, nerve growth factor, erytropoetin); and stimulation of bone metabolism/growth
(cartilage response to IGF1 and osteoblastic/osteoclastic bone remodelling).
Thermogenic genomic effects include stimulation of mitochondrial enzyme synthesis; stimu‐
lation of UCP-1 and UCP-3 in brown adipose tissue and muscle; and stimulation of membrane
Na/K ATPase. Metabolic genomic effects include induction of hepatic lipogenic enzymes;
stimulation of hepatic glutamine synthetase and α-aminolevulinic acid synthetase; potentia‐
tion of prolactin stimulation of lactalbumin synthesis; and potentiation of GH stimulation of
β2 euglobulin synthesis (Fisher & Gruters, 2008; Yen, 2001).
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The above effects do not occur immediately but only after hours of TR stimulation. However,
some TH effects occur immediately (e.g., stimulation of glucose transport and stimulation of
adrenergic receptor binding). Additionally, TH can regulate the number of beta-adrenergic
receptors in the heart and may thereby enhance sensitivity to catecholamines. Increased
catecholamine effects via increased beta–adrenergic receptor binding and post-receptor
responsiveness are prominent manifestations of the hyperthyroid state (tachycardia, tremor
and lid lag) and are manifested in the face of normal or lowered circulating concentrations of
catecholamines (Fisher, 1990).
4. Thyroid hormones and growth plate
The process of longitudinal bone growth is governed by a complex network of endocrine
signals, including growth hormone, IGF1, glucocorticoid, thyroid hormone, oestrogen,
androgen, vitamin D and leptin (Nilsson et al., 2005). The growth plate consists of three
principal layers: the resting zone, proliferative zone and hypertrophic zone. In hypothyroid
animals, the proliferative and hypertrophic zones are decreased in height, and chondrocyte
proliferation, chondrocyte hypertrophy and vascular/bone cell invasion are affected. In
addition, the normal columnar organisation of the growth plate is disrupted (Stivens et al.,
2000). Some of the sceletal effects appear to be due to direct action on the growth plate. Growth
plate chondrocytes express thyroid hormone receptor (TR) isoforms TR-α, α-1,and β. Most
cases of thyroid hormone resistance in humans are caused by dominant-negative mutations
of the TR-β gene, which may also affect TR-α function and show variable sceletal effects
(Takeda et al., 1992, Nilsson et al., 2005).
TH are critical for normal bone growth and development. In children, hypothyroidism can
cause short stature and delayed closure of the epiphyses. Biochemical studies have shown that
TH can affect the expression of various bone markers in the serum, reflecting changes in both
bone formation and resorption. TH increase alkaline phosphatase and osteocalcin in osteo‐
blasts. Additionally, osteoclast markers such as urinary hydroxiproline, urinary pyridinium,
and deoxypyridinium cross-links are increased in hyperthyroid patients. These observations
suggest that both osteoblast and osteoclast activities are stimulated by TH (Yen, 2001).
5. Levels of the thyroid hormone control
There are three levels of the regulation of thyroid hormone concentrations and actions: I
constant hormonal serum concentration is maintained by a feedback loop between the
hypothalamus, pituitary and thyroid. This centrally regulated system is not sufficient to
provide the necessary amount of TH for every tissue and cell in the body. II TH for local needs
are provided by the control and regulation of TH entrance by active transmembrane trans‐
porters and the tissue-specific action of activating enzymes (D1 and D2 deiodinase) and a
deactivating enzyme (D3 deiodinase), whose concentrations are regulated differently in each
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tissue. III The third level of the regulation of hormonal response depends on the type and
activity of TH receptors and is also active at the tissue-specific level. (Bianco et al., 2002; Van
der Deure et al., 2010).
Some tissues, such as muscle, have a relatively low deiodinase activity and are dependent, to
a great extent, on tri-iodothyronine derived from the thyroid and liver. Other tissues, such as
the brain and liver, have a high deiodinase activity, and the availability of tri-iodothyronine
is determined within the tissues themselves (Romijn et al., 2003).
Thyroxine-binding globulin (TBG) is the most important carrier protein for T4. In contrast,
TBG and albumin seem equally important for T3. The binding reactions are nearly complete,
and thus the euthyroid steady-state concentration of free T4 and T3 approximate 0.03% and
0.3% (respectively) of total hormone concentrations. TBG levels are higher in children than in
adults and decrease progressively to adult levels during adolescence (Fisher, 1990; Fisher &
Grueters, 2008).
6. Different forms of hypothyroidism and their impact on growth
6.1. Central (hypothalamic–pituitary) hypothyroidism
The prevalence of central hypothyroidism approximates 1 in 20,000 births. The most frequent
causes of the acquired form are irradiation of the head, chemotherapy for malignant disorders,
craniopharyngiomas, granulomatous disease, meningoencephalitis and head trauma. The
development of the pituitary gland as well as TSH gene expression is regulated by the multiple
pituitary transcription factors. Genetic mutation of these factors has been found to cause
familial hypopituitarism with TSH deficiency. The congenital form of central hypothyroidism
occurs in anencephaly, holoprosencephaly, septo-optic dysplasia (SOD), medial facial
syndromes, TSH β mutations, and HESX1, Pit-1, Prop-1 and LHX3/LHX4 mutations (Kelber‐
man & Dattani, 2008). Congenital central hypothyroidism is also associated with multiple
hormonal deficiencies. However, idiopathic forms of hypopituitarism are still often present
and hide some forms of autoimmune and congenital disorders (De Graaf et al., 2009).
Growth failure due to GH or TSH deficiency is usually the earliest manifestation of pituitary
hypofunction, but other features related to primary disease, neurologic disorder, or hypo‐
thalamic dysfunction may be prominent.
Isolated central hypothyroidism is an uncommon disorder associated with short stature in
children presenting with low free T4 and normal or low serum TSH concentrations without
other evidence of pituitary disease. The diagnosis of central hypothyroidism can be considered
in those with a serum free T4 level in the lower half of the normal range and normal TSH
concentrations. The TRH test is of diagnostic value in such circumstances.
The prevalence of isolated central hypothyroidism has been reported as 16% in a group of 181
children with idiopathic short stature (Rose, 1995).
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In our group of 59 children with growth hormone deficiency, 4 had pituitary dwarfism because
of the classic triad (Fig 1): a hypoplastic anterior pituitary, an ectopic posterior pituitary and
an invisible or transected pituitary stalk. In 10 children, pituitary structural lesions classified
as microadenoma were present on magnetic resonance imaging (MRI) examination (4 micro‐
prolactinomas and 6 non-functioning pituitary microadenomas). Two children experienced
hypopituitarism after head trauma, and an additional 2 experienced hypopituitarism because
of suprasellar tumours (germinoma, Fig 2, and teratoma). In one boy, an empty sella syndrome
was revealed.
Figure 1. MRI of boy with central hypothyroidism caused by pituitary hypoplasia.
Figure 2. MR sagittal scan of boy with suprasellar germinoma producing central hypothyroidism (TT4 62.41 nmol/L,
FT4 8.32 pmol/L, TSH 0.057 mIU/L).
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Hypointense pituitary lesions are an important sign of hypothalamic and pituitary dysfunction
and a distinguishing marker in children that should be considered for further investigation
and endocrinologic surveillance. Thus, MRI investigation is recommended as an effective
screening tool. MRI is an important option for use in further evaluation of short children and
resistant obesity accompanied by gonadal dysfunction and pubertal disorders.
6.2. Primary, overt hypothyroidism
The clinical manifestations of acquired hypothyroidism in childhood differ from those in
adults. The classic manifestations also occur in children but are not as prominent. Instead, the
most important sign of acquired hypothyroidism in childhood is a slowing of growth. Weight
tends to increase, and, in most instances, weight for age is greater than height for age. The
retardation of bone age in hypothyroidism usually equals or exceeds the retardation in linear
growth (Fisher, 1990; Hall, 1989; Saranac & Stamenkovic, 2012). Feeling cold, experiencing
fatigue, and displaying primary amenorrhoea with no impairment of school performance is
also commonly observed in children with acquired hypothyroidism. However, in some
children, deterioration in school work and learning difficulties might occur. Clinical signs of
severe acquired hypothyroidism unique to childhood are presented in Table 1. Mixedema,
generalised or discrete hair loss and firm, often smooth goitre with a palpable Delphian node
on the isthmus are clinical signs of autoimmune hypothyroidism. Clinical markers such as
segmental vitiligo, hypopigmented rings surrounding dark naevi (“halo naevi”), leukotrichia,
premature greying of the hair, and alopecia areata are all, like typical vitiligo, associated with
autoimmune disorders (Hall, 1989). An increased frequency of autoimmune thyroid disorders
is reported in Turner syndrome (TS) and other non-disjunctional chromosomal disorders, such
as Down syndrome, and these disorders seriously affect growth in these children. Hypothyr‐
oidism of autoimmune origin is so common in TS that almost every other TS girl will most
likely develop hypothyroidism, with the likelihood increasing with age (El-Mansoury et al.,







Table 1. Clinical signs of acquired hypothyroidism unique to childhood (Fisher, 1990)
In primary hypothyroidism, the anterior pituitary shows an increase in thyrotroph cells.
Hyperplasia or even adenoma formation may result from long-standing hypothyroidism,
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particularly hypothyroidism dating from infancy. Enlargement of the pituitary fossa has been
demonstrated, and suprasellar extension of the feedback tumour of the cells may occur rarely
(Hall, 1989). We recently published a case of a hypothyroid boy with severe growth failure
caused by long-standing, neglected hypothyroidism with very high thyrotropin levels and
sella enlargement (Saranac & Stamenkovic, 2012).
In cases of long-standing hypothyroidism, the dose of l-thyroxine should be increased
gradually to prevent cardiac failure. Most children respond well to a dose of 100 µg/m2 (Fisher,
1990; Fisher & Grueters, 2008). When clinical features such as loss of body hair occur and
increase the possibility of pituitary hypothyroidism, it is dangerous to treat the patient with
thyroid hormone without determining the plasma cortisol level and, if necessary, correcting
any adrenocortical deficiency (Hall, 1989).
In clinical practice, the adequacy of TH supplementation is assessed by the measurement of
TSH and fT4 concentrations. This approach deserves two comments. First, it is remarkable that
the normal values of TSH show a more than ten-fold variation. In clinical practice, because the
optimal TSH concentration within this range for individual patients is unknown, titration of
the substitution dose of thyroxine within this variation is relatively crude. Secondly, the
intrinsic assumption of many doctors using this approach is that a normal TSH concentration
reflects adequate TH concentrations not only at the tissue level of the hypothalamus and the
pituitary but also in other tissues. However, it is likely that this assumption is erroneous
(Romijn et al., 2003).
Some adults require combined l-T3 + l-T4 treatment, although the benefit in humans is
controversial. The rationale for this combined treatment is that monotherapy cannot provide
euthyroid state in all tissues of the hypothyroid subject. In rodents, it has been clearly dem‐
onstrated that there is no single dose of T4 or T3 that normalises TH concentrations simulta‐
neously in all tissues in hypothyroid animals (Escober-Morreale et al., 1996). Therefore, it is
highly likely that in patients treated with l-T4, subtle derangements at the tissue level are
present with respect to TH availability and, most likely, TH action. Unfortunately, we lack
sensitive signs and symptoms needed to evaluate this hypothesis in clinical practice, and we
do not have sensitive biochemical markers of TH action at the tissue level other than TSH
(Romijn et al., 2003).
Unlike insulin and cortisol levels, which fluctuate widely in response to food ingestion and
stress, thyroid hormones are typically maintained at a constant level, resulting in a proper
metabolic rate. Thyroid hormones are crucial for survival in both rodents and humans
(Zimmerman-Belsing et al., 2003). In many respects, thyroid hormones may be viewed as tissue
growth factors. Indeed, normal overall whole body growth does not occur in the absence of
thyroid hormones despite adequate levels of growth hormone (GH). TH also influence the
function of other endocrine systems. After 3 to 4 years of age, thyroid hormone deficiency is
not associated with mental retardation but delayed somatic and linear bone growth. Bone
maturation, measured as bone age, is also delayed; diaphyseal bone growth is reduced; and
epiphyseal growth and mineralisation largely cease. The effects of thyroid hormones on
somatic and skeletal growth are mediated by stimulation of the synthesis and action of growth
hormone and growth factors (Griffin & Ojeda, 1998).
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Thyroid hormones also potentiate growth hormone stimulation of insulin-growth factor
synthesis and action as well as GH and IGFs binding to the receptors and post-receptor events.
Additionally, TRH’s rise in primary hypothyroidism acts as suppressor of nocturnal growth
hormone pulses. In 1989, Chernausek et al. documented the attenuation of spontaneous
nocturnal growth hormone secretion in the hypothyroid state and the proportional fall in IGF1
serum concentration.
Catch-up growth is defined as a linear growth rate greater than expected for age after a
period of growth inhibition. Growth-inhibiting conditions conserve the limited prolifera‐
tive capacity of  growth plate chondrocytes,  thus showing the normal process of  growth
plate senescence. When the growth-inhibiting condition resolves, the growth plates are less
senescent and therefore grow more rapidly than normal for age (Marino et al., 2008,; Shao
et al., 2006). If the hypothyroid state is prolonged prior to treatment, catch-up growth may
be incomplete.  Excessive dosage is  marked by disproportionate advancement in skeletal
age (Fisher & Grueters, 2008).
In  1991,  Pantsiouou found that  in  spite  of  appropriate  treatment,  primary hypothyroid‐
ism results in permanent growth failure.  In girls,  normal harmony between growth and
pubertal maturation has been disturbed or lost. Growth continued after menarche, but final
height  remained  far  below  the  age  average  and  predicted  height  according  to  mid-
parental  height.  That  is  why  some  authors,  including  Minamitani,  recommended  the
combined treatment with GnRH analogues and GH, besides substitutional l-T4 treatment
for optimal growth stimulation.
6.3. Subclinical hypothyroidism
Subclinical hypothyroidism (SCH) is defined by an elevation of serum TSH with circulat‐
ing free thyroid hormone concentrations that are within the reference range (Evered et al.,
1973; Cooper & Biondi 2012). SCH is a common issue in clinical practice that predominant‐
ly affects women and has a prevalence of between 2 and 10%, which increases in an age-
related  fashion.  More  than  three-quarters  of  individuals  with  SCH  have  serum
concentrations between 5 and 10 mU/l. Although treatment of the mild thyroid failure of
SCH with levothyroxine (l-T4) would seem to be a logical approach to management, only
a minority  of  individuals  with SCH have symptoms that  are  typical  of  hypothyroidism
(Pearce et al.,  2012). According to one of the few available follow-up studies on juvenile
SCH, this may be a benign and remitting process with a very low risk of evolution toward
frank hypothyroidism (Raillison et al., 1975; Moore, 1996).
There is great controversy concerning the clinical significance of SCH and whether or when
subjects with SCH should be treated with l-T4. In adults,  SCH has been associated with
several  complications,  such  as  progression  into  overt  hypothyroidism,  abnormalities  of
lipid  profile,  increased  risk  of  atherosclerosis  and cardiovascular  morbidity  and clinical
signs and symptoms of  mild disease,  including impaired cognitive function (Cerbone et
al., 2011). Treatment is currently recommended in SCH subjects with a TSH value above
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10 mU/l, whereas treatment for TSH levels between 4.5 and 10 mU/l remains a matter of
debate (Wiersinga et al., 2012).
In children, SCH is not yet a well-defined condition due to both the low prevalence of this
disorder and the lack of long-term studies.
Some children with CAT experience all types of thyroid dysfunction during the natural course
of the disease: mild hyperthyroidism at diagnosis (hashitoxicosis), euthyroid state and gradual
progression from subclinical to overt hypothyroidism. An intriguing form of CAT could be
subclinical hypothyroidism with mixed signs of hypo- and hyperfunction ("autoimmune
dysthyroidism"). Thus, clinical features do not always correspond to hormonal status. The
reasons for diagnostic pitfalls, including clinical ambiguity, are challenging for pediatricians
and endocrinologists (Saranac & Stamenkovic, 2012).
Even though subclinical hypothyroidism is defined as an asymptomatic disorder in which
a euthyroid state is maintained due to TSH elevation, in our experience, this dysfunction
type actually has clinical expression despite being labelled as mild, subclinical or compen‐
sated. Tunbridge recorded clinical features in adults, which included cold intolerance, dry
skin, lack of energy, puffiness around the eyes, acroparaesthesiae and weight gain, and the
signs elicited included periorbital swelling, scaling of the skin and a slow pulse rate (minor
degrees of hypothyroidism) (Hall, 1989). In children, even the subclinical form of hypothyr‐
oidism  has  an  impact  on  growth,  weight  regulation,  bone  maturation  and  pubertal
development.
While the mild clinical picture of hypothyroidism is expected in children, the appearance of
the opposite hyperfunction signs in subclinically hypothyroid subjects is intriguing. A possible
explanation could be the rise in TRH with neurotransmitter properties that leads to release of
TSH, PRL, FSH, and noradrenalin (NA). Tachycardia, nervousness, and emotional lability in
subclinically hypothyroid subjects could be attributed to NA released in this way. Moreover,
the turnover of NA in the brain of hypothyroid subjects has been found to be elevated
(Jovanovic-Micic et al., 1991; Bauer et al., 2008).
The ambiguity in the clinical picture could also be explained by the presence of heterogenic
antibodies to the TSH receptor in the same subject. A transient shift from blocking to stimu‐
lating antibodies may provoke hyperthyroid signs in the hypothyroid subject (Song et al.,
1996; Saranac et al., 2003, 2010).
Reasons not to treat SCH in adults are numerous. Serum TSH is not a perfect marker of
thyroid hormone action because of its dependence on hypothalamic TRH, type 2 deiodi‐
nase,  and  the  influence  of  steroids,  cytokines,  adipokines  and  neuromediators  (e.g.,  l-
dopa).  Increased  TSH  is  not  a  fixed  and  immutable  parameter:  it  varies  according  to
diurnal,  circannual,  and physiological  and non-thyroidal  factors.  Normal  values  of  TSH
can differ ten-fold within normal reference values. Obesity is a circumstance in which high
levels  of  TSH  are  frequently  discovered,  although  a  lack  of  thyroid  hormone  is  not
generally  the  culprit.  Furthermore,  therapy  with  levothyroxine  is  not  free  of  inconven‐
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ience and risks. Finally, extreme longevity is associated with increased serum thyrotropin
levels (Pearce et al., 2012).
In growing child, there are scarce data regarding the evaluation of substitution benefits.
Thus, the dilemma of whether to treat subclinical hypothyroidism is still in question. The
problem is further complicated by the fact  that obese children do present with elevated
values of TSH. Several mechanisms leading to hyperthyrotropinaemia have been hypothes‐
ised, including increased leptin-mediated production of pro-TRH, impaired feedback due
to a decreased number of T3 receptors in the hypothalamus, and variations in peripheral
deiodinase  activity  (Radetti  et  al.,  2008).  With  respect  to  growth  in  SCH,  there  are
ambiguous data. In a prospective evaluation of the natural course of idiopathic subclini‐
cal  hypothyroidism in childhood and adolescence,  Wasniewska et  al  (2009) did not find
any  association  between  TSH  changes  and  FT4  values,  clinical  status  or  auxological
parameters. The study group consisted of 92 patients (50 boys) with idiopathic SCH. The
majority of the patients (88%) normalised or maintained their TSH levels during the 24-
month  follow-up  period.  Stature  was  within  normal  limits  at  diagnosis  and  remained
normal at the end of the study. In a cross-sectional controlled study, Cerbone et al (2011)
evaluated growth and intellectual outcome in 36 children with persistent SCH who had
never been treated with levothyroxine and in the same number of age- and sex-matched
controls.  The  authors  concluded  that  persistent  SCH  in  children  is  not  associated  with
alterations in growth, bone maturation, BMI, and cognitive function or other complaints
that could be ascribed to SCH even after several  years.  However,  the mean duration of
follow up was only 3.3 years.
In 17 paediatric patients with SCH, Ergur et al. (2012) documented poor performance on tests
measuring attention and neurocognitive capabilities. No significant differences were found
between the SCH group and the healthy controls in verbal fluency and encoding tests.
In a small study of 16 children with SCH and diagnosis of CAT, we found suboptimal growth
velocity (4.12 cm/year), which significantly improved up to 7.36 cm/year (p<0.05) after 12
months of treatment. Mean bone age advancement was 1.6 years/year and did not exceed
growth acceleration (1.98 years/year), due to careful dose monitoring. Despite appropriate
treatment with l-T4, the mean SD score of height for chronological age remained unachieva‐
ble in comparison with euthyroid, non-treated CAT patients (Fig 3). During treatment, the
T3/T4 ratio in the treated group showed a sharp rise after 1 year of treatment, in accord‐
ance with the mean best growth velocity during follow-up period of mean 2.19 years (range
1-4 years) (Fig 4). The mean TSH of the SCH group was 8.98 mU/ml at diagnosis, falling
gradually to 4.81 mU/ml after 1 year and 1.98 mU/ml after 2 years of treatment. We conclud‐
ed that children with SCH had suboptimal growth before treatment, which improved during
l-T4  substitution,  with  simultaneous  normalisation  of  TSH  levels.  In  addition  to  other
favourable effects on thyroid volume and thyroid autoimmunity markers, TH isohormonal
therapy provides optimal growth in children with CAT. However, caution is recommended
in children who are simply obese, where, despite elevated TSH, l-T4 treatment should be
avoided or cautiously considered.
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Figure 3. Standard deviation score (SD) changes during follow-up in hypothyroid children (overt+ subclinical hypo‐
thyroidism) in comparison with non treated (euthyroid and hyperthyroid). Growth is reflection of thyroid function.
Figure 4. T3/T4 ratio changes in l-thyroxine treated versus non treated children.
7. Conclusion
Screening for congenital hypothyroidism achieved the historical goal of eliminating the most
serious endocrine cause of mental retardation, hypothyroid cretinism. However, acquired
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hypothyroidism remains a frequent cause of interruption of statutoponderal progress, failure
to thrive and growth impairment. Dynamic growth is a fundamental characteristic of happy,
healthy children who are well nourished and nurtured. Stature represents a phenotypic
characteristic that produces significant anxiety in children and their families. A euthyroid state
is crucial in this complex, synergistic process in which nutrition, emotions and hormones act
simultaneously. Growth is a reflection of thyroid function. Thus, the first step in the hormonal
investigation of children with growth failure is the thyroid function assessment. Pediatricians
must be educated to select patients suspected of hypothyroidism, to document different forms
of hypothyroidism and to treat them properly while simultaneously being attentive to false
positive results.
Although hormonal substitution therapy in the treatment of hypothyroidism is extremely
successful and has fulfilled its promises, a perfect mimicry of endocrine homeostasis by thyroid
hormone replacement is, in general, impossible, especially in growing children.
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